Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.
Ho
D D
DD
Aaron Diamond AIDS Research Center, NYU School of Medicine, New York 10016.
Neumann
A U
AU
Perelson
A S
AS
Chen
W
W
Leonard
J M
JM
Markowitz
M
M
D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000821:virology*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007700:Kinetics; D019438:Ritonavir; D014766:Viremia / Q000188:drug therapy / Q000821:virology*; D014771:Virion / Q000502:physiology; D014779:Virus Replication
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D019438:Ritonavir